Objective: The transfer of anti-human immunodeficiency virus (HIV) drugs has been studied in the ex vivo human placental model. There is a paucity of information on the placental transfer of these drugs because of ethical considerations and the expense involved in the use of the non-human primate model.
Because HIV mutates very readily and becomes resistant to single drug therapy, the use of combination therapy with two nucleoside inhibitors, and more aggressively two nucleoside inhibitors and a protease inhibitor, may be necessary for the prevention of perinatal transmission of the virus. The purpose of this review is to examine the published perfusion model data involving non-nucleoside and nucleoside inhibitors alone and in combination. Studies on the combination of a nucleoside inhibitor and a protease inhibitor also are included.
Studies on the pharmacology and teratology of the anti-HIV nucleosides in animal models and ex vivo systems are useful prior to the use of these inhibitors for treatment of HIV positive pregnant women. Among the nucleosides involved in teratology studies were 2'-3'-dideoxycytidine (ddC), 2'-3-dideoxyinosine, which is now didanosine (ddI), and AZT. In rat embryo culture studies, a minimum of 40% of embryos developed abnormality with AZT, while other drugs showed a higher interference with embryonic development. In experiments with pregnant rats treated with 200 mg/ kg of each drug 3 times/day (600 mg/kg), there were no subsequent abnormal developments noted on day 10 . 4, 5 However, subsequent studies did identify pregnancy resorption at dose.levels 15 times the normal human dose of 300 mg BID (2, 250 mg/kg) under similar conditions. This is consistent with several studies showing the embryolethal effect of postimplantation in rats and preimplantation of mouse embryos. [4] [5] [6] [7] [8] The current American College of Obstetricians and Gynecologists (ACOG) recommendation for the treatment of pregnant women is 100 mg of zidovudine (AZT) 5 In vivo AZT pharmacokinetic studies in three pregnant HIV positive women were done at 19, 30, and 33 weeks with no unusual side effects. Amnionic fluid levels were high in the cord blood levels, suggesting fetal renal excretion and accumulation of the drug by the infant in the amnionic fluid.
In addition, cord blood levels were 113-127% higher than maternal levels. 19 These data confirm transplacental transport and fetal accumulation in both the in vivo and the ex vivo human placental Table 1 . Further studies, with these nucleoside inhibitors indicated there were no significant changes in the Ci when ddl, ddC, d4T, and 3TC were used in combination with therapeutic and 10x concentrations of AZT. When endogenous bases and the inhibitor dipyridamole were added to placental perfusion studies with these anti-HIV nucleoside inhibitors, there were no changes in the Ci, suggesting no transport system and no adverse effects of the combination. Thus, the compounds cross from the maternal to the fetal compartment by simple diffusion. 16-zl In a recent open label pilot study (NUCB2018) in South Africa using 3TC alone and AZT along with 3TC in combination, 20 HIV pregnant women were given 8 mg/kg/day (300 mg BID) of 3TC or 4 mg/kg/day (150 mg/kg BID) 3TC plus 8 The non-nucleoside reverse transcriptase inhibitor used in these studies was bisheteroypiperazine (U-87201-E). 29 The studies with U-87201-E suggest a rapid diffusion of the drug at therapeutic concentrations of 1.0 and 20 pg/ml with a Ci of 0.72 _+ 0.17. This Ci is twice that of AZT, and 5 times that of ddI. Placental tissue concentrations were near those of the maternal blood concentration, suggesting saturation. 29 
CONCLUSIONS

